X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20553) 20553
Book Review (5117) 5117
Publication (1464) 1464
Magazine Article (114) 114
Conference Proceeding (81) 81
Book Chapter (34) 34
Book / eBook (13) 13
Dissertation (10) 10
Paper (6) 6
Trade Publication Article (6) 6
Web Resource (6) 6
Government Document (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18905) 18905
index medicus (18853) 18853
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (16428) 16428
male (10091) 10091
female (9058) 9058
statins (7634) 7634
middle aged (7325) 7325
aged (6452) 6452
risk factors (4752) 4752
cholesterol (3971) 3971
cardiac & cardiovascular systems (3886) 3886
treatment outcome (3697) 3697
adult (3588) 3588
abridged index medicus (3584) 3584
animals (3257) 3257
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (3202) 3202
pharmacology & pharmacy (3017) 3017
simvastatin (2875) 2875
cholesterol, ldl - blood (2857) 2857
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (2629) 2629
atorvastatin (2598) 2598
risk (2461) 2461
medicine, general & internal (2455) 2455
hypercholesterolemia - drug therapy (2429) 2429
cardiovascular diseases - prevention & control (2396) 2396
prevention (2303) 2303
anticholesteremic agents - therapeutic use (2178) 2178
cardiovascular disease (2106) 2106
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (2089) 2089
atherosclerosis (2080) 2080
peripheral vascular disease (2052) 2052
therapy (1996) 1996
mortality (1909) 1909
coronary-heart-disease (1874) 1874
atorvastatin calcium (1867) 1867
pravastatin (1851) 1851
aged, 80 and over (1829) 1829
drug therapy (1743) 1743
lipids (1606) 1606
heptanoic acids - therapeutic use (1581) 1581
time factors (1564) 1564
pyrroles - therapeutic use (1561) 1561
retrospective studies (1559) 1559
statin (1557) 1557
cholesterol - blood (1554) 1554
analysis (1535) 1535
drug therapy, combination (1517) 1517
care and treatment (1511) 1511
simvastatin - therapeutic use (1454) 1454
cardiovascular (1441) 1441
myocardial-infarction (1440) 1440
hypercholesterolemia (1428) 1428
disease (1405) 1405
cardiovascular-disease (1394) 1394
hypolipidemic agents - therapeutic use (1371) 1371
research (1359) 1359
c-reactive protein (1347) 1347
cardiovascular diseases (1334) 1334
randomized controlled trials as topic (1312) 1312
risk assessment (1296) 1296
prospective studies (1284) 1284
inflammation (1249) 1249
dyslipidemias - drug therapy (1225) 1225
follow-up studies (1209) 1209
metaanalysis (1182) 1182
hyperlipidemias - drug therapy (1161) 1161
cardiovascular agents (1160) 1160
cardiology (1153) 1153
lipids - blood (1150) 1150
health aspects (1132) 1132
coronary heart disease (1102) 1102
cholesterol, hdl - blood (1096) 1096
medicine & public health (1076) 1076
internal medicine (1059) 1059
hydroxymethylglutaryl-coa reductase inhibitors (1056) 1056
practice guidelines as topic (1045) 1045
rosuvastatin calcium (1045) 1045
double-blind method (1021) 1021
rats (1007) 1007
secondary prevention (1006) 1006
diabetes (1004) 1004
rosuvastatin (999) 999
triglycerides - blood (990) 990
biomarkers - blood (989) 989
primary prevention (987) 987
clinical trials as topic (982) 982
dose-response relationship, drug (974) 974
low density lipoproteins (970) 970
cohort studies (967) 967
statin therapy (923) 923
angiotensin-converting enzyme inhibitors - therapeutic use (897) 897
pravastatin - therapeutic use (894) 894
events (888) 888
antilipemic agents (872) 872
coronary disease - prevention & control (862) 862
coa reductase inhibitors (857) 857
fluorobenzenes - therapeutic use (851) 851
hypercholesterolemia - blood (847) 847
platelet aggregation inhibitors - therapeutic use (846) 846
sulfonamides - therapeutic use (836) 836
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19179) 19179
German (282) 282
French (217) 217
Spanish (207) 207
Japanese (191) 191
Russian (114) 114
Italian (93) 93
Chinese (67) 67
Polish (54) 54
Hungarian (44) 44
Czech (39) 39
Dutch (34) 34
Swedish (29) 29
Portuguese (27) 27
Turkish (25) 25
Danish (18) 18
Finnish (16) 16
Norwegian (10) 10
Ukrainian (10) 10
Serbian (9) 9
Hebrew (7) 7
Croatian (6) 6
Romanian (6) 6
Bosnian (3) 3
Korean (2) 2
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Liver | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
Summary Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible... 
Internal Medicine | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Index Medicus | Abridged Index Medicus | Klinisk medicin | Clinical Medicine
Journal Article